About Us
Meet the Team
Conditions & Procedures
Conditions
Procedures
Patient Center
Research
Education & Training
News & Events
Make a Gift
A gift to the Thoracic Oncology Progam helps us discover new treatments and cures for lung cancer, esophageal cancer and mesothelioma.
Research Fellow Johannes Kratz, M.D. Leaves Lasting Mark on Lab
Johannes Kratz, M.D., a research fellow in the Thoracic Oncology Lab from 2008-11, played a pivotal role in the development of a prognostic assay for early-stage lung cancer patients, reported on in The Lancet and JAMA.
Thierry Marie Jahan, M.D.
Associate Professor of Medicine
Bonnie J. and Anthony Addario Endowed Chair in Thoracic Oncology
Director, Clinical Services, Division of Hematology/Oncology
Contact Information
BiographyEducation
- 1977-1980, Université de Paris V-René Descartes, Paris France
- 1980-1983, Columbia College, NYC, NY, BA, Psychology
- 1983-1987, George Washington University School of Medicine, Washington, DC, M.D.
Residencies
- 1987-1988, Cedars Sinai Med. Ctr/UCLA, Los Angeles, CA, Internship, Internal Medicine
- 1988-1990, Cedars Sinai Med. Ctr/UCLA, Los Angeles, CA, Resident, Internal Medicine
Fellowships
- 1990-1991, Cedars Sinai Medical Ctr/UCLA, Los Angeles, CA, Kennamer Fellow in Internal Medicine
- 1991-1994, UCSF, San Francisco, CA, Hematology/Oncology Fellow
Board Certification
- American Board of Internal Medicine, Internal Medicine
- American Board of Internal Medicine, Hematology
- American Board of Internal Medicine, Medical Oncology
Program Affiliations
- Department of Medicine, Division of Hematology Oncology, Thoracic Oncology Program
- Member, UCSF Helen Diller Family Comprehensive Cancer Center
Clinical Expertise
- Bronchioloalveolar Carcinoma (BAC)
- Carcinoid Tumors
- Chest Wall Tumors
- Malignant Mesothelioma
- Mediastinal Masses
- Multi-modality Therapy
- Non-Small Cell Lung Cancer
- Pulmonary Metastases
- Sarcoma
- Small-Cell Lung Cancer
- Tracheal Tumors
Research Interests
- Novel agents in mesothelioma non-small cell lung cancer
Biography
Thierry Jahan, M.D. is the one of the region's foremost and highly regarded thoracic oncologists. Dr. Jahan has devoted his life to treating patients with lung cancer, mesothelioma and sarcoma. In addition to his keen clinical insight, Dr. Jahan is known by patients, their families and fellow clinicians for his sense of empathy and compassion. His commitment to wiping out lung cancer can be seen in the pins and ribbons that adorn his white coat, a message of hope he carries symbolically to patients as they battle a cruel disease.
Dr. Jahan received his M.D. from George Washington University. He completed his residency and an internal medicine fellowship at Cedars Sinai Medical Center in Los Angeles, followed by a fellowship in hematology and oncology at UCSF. In 1994, Dr. Jahan joined the UCSF faculty and later, with Dr. David M. Jablons, cofounded the Thoracic Oncology Program. Dr. Jahan currently holds the title of Associate Professor of Medicine at the UCSF School of Medicine.
Dr. Jahan has been the recipient of numerous awards including the Medical House Staff Outstanding Teacher Award and Friend of the Palliative Care Service Award. He is also a member of numerous professional organizations, including the American College of Physicians, American Society of Clinical Oncology (ASCO), and International Association for the Study of Lung Cancer (IASLC) and the Association of Northern California Oncologists.
Dr. Jahan has authored or co-authored numerous peer-reviewed articles, book chapters and research abstracts and lectured nationally and internationally on lung cancer and mesothelioma. The San Francisco Chronicle, Time Magazine and KPIX in San Francisco have each sought out his insights and observations on the clinical and human side of battling serious life-threatening cancers.
Research Summary
Dr. Jahan is Principal Investigator on numerous thoracic oncology clinical trials. He has a particular interest in testing target therapies in non-small cell lung cancer malignant mesothelioma as either single agents or in combination with chemotherapy and/or radiation.
Clinical Trials
Selected Publications
-
Radical Pleurectomy/Decortication and Intraoperative Radiotherapy Followed by Conformal Radiation with or without Chemotherapy for Malignant Pleural Mesothelioma. Lee TT, Everett DL, Hui-Kuo G, Jahan TM, Roach M, Speight JL, Cameron RB, Philips TL, chan A, Jablons DM. Journal of Thoracic and Cardiovascular Surgery 124(6): 1183-89, 2002
-
Unusual Thoracic Problems in Patients with Malignancies: CASE 3. Carcinoid Tumor of the Thymus. Hansen EK, Krieg RM, Azar RJ, Jablons DM, Jahan TM. Journal of Clinical Oncology 23(12): 2859-2861, 2005
-
Activating Mutations in the Tyrosine Kinase Domain of the Epidermal Growth Factor Receptor are Associated with Gefitinib Response in Chemorefractory Lung Adenocarcinomas. Taron M, Ichinose Y, Rosell R, Mok T, Massuti B, Zamora L, Mate JL, Manegold C, Ono M, Queralt C, Jahan T, Sanchez JJ, Ronco MS, Hsue V, Jablons D, Sanchez JM, Moran T. Clinical Cancer Research 11(16):5878-85, 2005.
-
Phase 1/2 Trial of Autologous Tumor mixed with an Allogeneic GVAXÒ Vaccine in Advanced Stage Non-Small Cell Lung Cancer. Nemunaitis J, Jahan T, Ross H, Sterman D, Richards D, Fox B, Jablons D, Aimi J, Banik G, Hege K. Cancer Gene Ther. 2006 Jun; 13(6):555-62.
-
Small cell lung cancer clinical practice guidelines in oncology. Johnson BE, Crawford J, Downey RJ, Ettinger DS, Fossella F, Grecula JC, Jahan T, Kalemkerian GP, Kessinger A, Koczywas M, Langer CJ, Martins R, Marymont MH, Niell HB, Ramnath N, Robert F, Williams CC Jr; National Comprehensive Cancer Network (NCCN). J Natl Compr Canc Netw. 2006 4(6): 602-22.
In the News
Mulitgene Assay Better Predictor of Survival than Conventional Staging
The Lancet - UCSF News Center - Medscape Medical News - Jan 26, 2012
In the two largest clinical studies ever conducted on the molecular genetics of lung cancer, an international team, led by UCSF thoracic surgeons David M. Jablons, M.D. and Michael Mann, M.D., demonstrated that a 14-gene prognostic molecular assay better predicted the likelihood of death in early-stage lung cancer patients versus conventional staging guidelines. Johannes Kratz, M.D., a former surgical resident in the Thoracic Oncology Laboratory, helped spearhead the development of the assay and was lead author of a paper published in The Lancet discussing the results. John Minna, M.D.", Max L. Thomas Distinguished Chair in Molecular Pulmonary Oncology at UT Southwestern lauded the results, stating that the assay was "head and shoulders" above the rest and ready for "prime time" clinical use.
New Lung Cancer Test Predicts Survival (by Jason Bardi - UCSF News Center)
Genetic Test for Early Stage Lung Cancer (Video Interview with Johannes Kratz, M.D.)
David Jablons Audio Interview with The Lancet
New Lung Cancer Assay Ready for Prime Time (Medscape Oncology News)
Thoracic Oncology Program - The Year in Review
Thoracic Oncology Program - Aug 04, 2011Every July, the Thoracic Oncology Program provides a summary update of its accomplishments during the prior twelve (12) months. The program continues to grow and innovate. General Thoracic Surgery continues to innovate and expand the number of minimally invasive procedures it performs. The program's status as the busiest on the West Coast and the best place to refer complex and challenging cases continues. With a strong multidisciplinary team including UCSF Medical Oncology, Radiation Oncology and Pulmonology, the program continues to offer state-of-the-art care for the region and beyond.
Thierry Jahan, M.D. Honored with Exceptional Physician Award
UCSF Medical Center and Department of Surgery - Apr 21, 2010Thierry Jahan, M.D., an Associate Professor of Medicine Bonnie J. and Anthony Addario Endowed Chair in Thoracic Oncology, is one of four recipients of the 2010 UCSF Medical Center Exceptional Physician Award, an honor recognizing dedication to outstanding patient care and to the instiutions' values of Professionalism, Respect, Integrity, Diversity and Excellence. One of the region's most highly regarded thoracic oncologists and sarcoma specialists.
UCSF Celebrates Award of New Chair to Thierry Jahan, M.D.
Department of Surgery at UCSF - Jun 01, 2009The Bonnie J. and Anthony Addario Endowed Chair in Thoracic Oncology has been created in the Department of Surgery in honor of Thierry Jahan, M.D., an Associate Professor of Medicine at UCSF, who will occupy the Chair as its first recipient. Dr. Jahan is the one of the region's most highly regarded thoracic oncologists and sarcoma specialists, known among patients, their families, and colleagues for his deep sense of empathy and compassion. Dr. Jahan co-founded the multidisciplinary Thoracic Oncology Program with David Jablons M.D.. On July 9, 2009, there was a celebration held at the Kalmonovitz Library at UCSF to honor Dr. Jahan and his appointment to the newly created Chair.
Advancing the Treatment of Adult Soft Tissue Sarcomas
Orthopedic Surgery News at UCSF Medical Center - Dec 25, 2008"Soft tissue sarcomas are extraordinarily heterogeneous, so experience is particularly important when deciding among treatment options," says medical oncologist Thierry M. Jahan, M.D. (pictured right). At UCSF, referring physicians typically send patients with painful, growing soft tissue masses to orthopedic surgeon Richard J. O'Donnell, M.D., and general surgeon Eric K. Nakakura, M.D., Ph.D, (pictured left). If their initial examination convinces them that there is a sarcoma concern, they move on to a staging workup that includes various imaging modalities and, eventually, either a needle or incisional biopsy...."
